A PHASE 2 STUDY OF THE JAK1/JAK2 INHIBITOR RUXOLITINIB WITH CHEMOTHERAPY IN CHILDREN WITH DE NOVO HIGH-RISK CRLF2-REARRANGED AND/OR JAK PATHWAY-MUTANT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

59th Medical Wing at the Wilford Hall Ambulatory Surgical Center (WHASC)

BioBridge Global

Biomedical Development Corporation

Brooke Army Medical Center

Cancer Insight, LLC

EO2

Naval Medical Research Unit San Antonio (NAMRU-SA)

South Texas Veterans Health Care System and Foundation for Advancing Veterans Health Research

Southwest Research Institute

StemBioSys

Texas Biomedical Research Institute

The University of Texas at San Antonio

Trinity University

UT Health San Antonio

Bioscience Research Panel